DISCLAIMER — Not financial advice. Educational content only, not an offer or solicitation to buy or sell any security. Biotech and small/mid-cap stocks are highly speculative and volatile and can result in a partial or total loss of capital. Do your own research and consult a licensed advisor where appropriate. / Contenuti a solo scopo informativo e didattico, non costituiscono consulenza finanziaria né offerta o sollecitazione al pubblico risparmio ai sensi delle normative CONSOB e SEC. Le azioni biotech e le small/mid cap sono strumenti altamente speculativi e volatili e possono comportare la perdita parziale o totale del capitale investito. Si raccomanda di effettuare sempre le proprie ricerche e, se necessario, di rivolgersi a un consulente abilitato.
Merlintrader Trading Pub
Biotech catalyst news and analysis. FDA PDUFA tracker
Merlintrader Trading Pub
Biotech catalyst news and analysis. FDA PDUFA tracker
Category Members
CUE Emergency Deep Dive
Cue Biopharma is a clinical-stage biopharmaceutical company developing a novel class of injectable biologics designed to selectively engage and modulate disease-specific T cells using its Immuno-STAT platform, targeting both autoimmune disease and cancer.
RCKT Rocket Pharmaceuticals Inc
Rocket Pharmaceuticals is a gene therapy-focused company with disclosed programs across lentiviral (hematology) and AAV (cardiovascular) platforms, as described in SEC-filed materials.
GRCE Grace Therapeutics
Grace Therapeutics has disclosed that it submitted an NDA for GTx-104 (intravenous nimodipine) on June 25, 2025, and that the FDA accepted the application for review with a PDUFA target date of April 23, 2026.